Together with the University of Lund, Sweden, AMT is diligently working on the preclinical development of a gene therapy for delivery of the GDNF gene to the brain. Efficacy data in an animal model of PD is anticipated to be available by the end of the current year
Elevated levels of cholesterol are a major risk factor and contributor to the development of atherosclerosis and cardiovascular disease (CVD). Early research at AMT demonstrates that after a single intravenous injection of a silencing gene therapy in animal models, the serum cholesterol levels were reduced by 80% with no signs of toxicity. It is therefore reasonable to expect a similar effect in patients, resulting in reduced risk for atherosclerosis or CVD. Such a long-term, perhaps life-long active gene therapy could eliminate the need for maintenance statin therapy.
Supervisory Board changes
During the period ended June 30, 2010, Alexander Ribbink and George Morstyn retired from the Supervisory Board and AMT thanks them for their substantial contributions. On April 28, 2010, AMT's co-founder Sander van Deventer was appointed to the Supervisory Board, and in addition Joseph M. Feczko, Steven H. Holtzman and Francois Meyer were nominated to the Supervisory Board for consideration at the Extraordinary General Meeting to be held on September 20, 2010.
Total net loss for the period ended June 30, 2010 amounted to EUR 9.4 million, in line with the net loss for the period ended June 30, 2009 which also amounted to EUR 9.4 million.
The main item wit
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2010 PR Newswire.
All rights reserved